Collegium Pharmaceutical experienced a strong second quarter in 2026, marked by notable advancements in its ADHD product line and a continued focus on its pain management offerings. The company's total net product revenue saw a 6% increase year-over-year, reaching $199.9 million. This growth was largely propelled by the impressive performance of Jornay PM, which recorded $46.1 million in revenue, a substantial 41% surge compared to the previous year. Furthermore, the strategic acquisition of Azstarys in May contributed $12.9 million in commercial sales during its initial period under Collegium’s ownership, indicating a promising start for the newly integrated product.
Despite the success in its ADHD division, the pain management portfolio presented a mixed performance. Belbuca demonstrated resilience with a 10% revenue increase to $57.7 million, attributed to consistent prescription demand. However, Xtampza ER experienced a 14% decline in revenue, settling at $45 million, primarily due to heightened market competition and a less favorable comparison to the previous year's rebate settlements. The NUCYNTA franchise also faced headwinds, with revenue dropping by 24% to $35.2 million, mainly due to the lower net pricing of its authorized generic products. In response to these dynamics, Collegium adjusted its full-year 2026 financial guidance, increasing the outlook for Azstarys to $65 million-$75 million, while slightly revising total product revenue expectations to $825 million-$855 million and adjusted EBITDA to $445 million-$470 million.
Looking ahead, Collegium Pharmaceutical is committed to its strategic priorities, including driving further growth in its ADHD portfolio, optimizing the profitability and longevity of its pain management products, and employing a disciplined approach to capital allocation. The company's robust cash flow and profitability provide a solid foundation for investing in growth opportunities, reducing debt, and returning capital to shareholders. With the successful integration of Azstarys and an expanded sales force targeting 27,000 healthcare providers, Collegium is well-positioned for sustained growth, particularly with the upcoming back-to-school season expected to boost ADHD medication sales. The company's dedication to innovation and patient-centric solutions underscores its vision for long-term success and value creation within the biopharmaceutical sector.
In a dynamic healthcare landscape, companies like Collegium Pharmaceutical exemplify the spirit of innovation and adaptability. By focusing on differentiated products and strategic acquisitions, they not only achieve financial milestones but also contribute significantly to patient well-being. This forward-thinking approach, coupled with sound financial management, paves the way for a future where medical advancements continue to improve lives and inspire progress.
